ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Treatment of BK Virus with Weekly Intravenous Immunoglobulin in Adult Kidney Transplant Recipients

G. Girone1, W. Asch2

1Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, 2Section of Nephrology, Yale School of Medicine, New Haven, CT

Meeting: 2022 American Transplant Congress

Abstract number: 1355

Keywords: Infection, IVIG, Kidney transplantation, Polyma virus

Topic: Clinical Science » Infection Disease » 26 - Kidney: Polyoma

Session Information

Session Name: Kidney: Polyoma

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: The typical management of Polyoma BK virus (BKV) in kidney transplant recipients (KTR) includes reducing immunosuppression (IS). Intravenous immunoglobulin (IVIG) has been utilized for BKV management with various dosing strategies. This report reviews the use of 0.1 g/kg weekly of IVIG as treatment for persistent BKV.

*Methods: This retrospective chart review included all adult KTR at Yale New Haven Hospital with BKV receiving IVIG 0.1 g/kg weekly for 10 weeks. All patients previously underwent reduction of maintenance IS without clearance of BKV. Those receiving any other IVIG dosing strategy and or with <6 month follow-up were excluded. Persistent BKV was defined as PCR >3 Log10 copies/mL despite IS reduction. Clearance was defined as undetectable viral load or <3 Log10 copies/mL . Patient demographics, BKV log10, and serum creatinine (SCr) were collected at 3 and 6 months. Rates of biopsy proven rejection (BPAR) and graft loss were also collected.

*Results: 29 adult KTR with BKV who received IVIG 0.1 g/kg weekly for 10 weeks were included. The majority of patients were received alemtuzumab induction (58.6%), were on a tacrolimus (79.3%) and were a median of 379 (137-1047) days from transplant. BKV-associated nephropathy was biopsy confirmed in 79.3%. The average cumulative amount of IVIG given was 59.5 g. Mycophenolic acid (MPA) was stopped prior to IVIG in 96% of patients. There was a significant reduction in average BKV log10 from baseline to 3 months (5.15 vs. 3.14, p<0.0003) and 6 months post-IVIG (5.15 vs. 2.47, p<0.0001). Viral clearance occurred in 65% of patients at a median of 263 days (IQR 56-608) from last IVIG. Only 1 patient was changed to everolimus during IVIG, and no other alternative BKV treatments were utilized. BPAR occurred in 3 patients after starting IVIG and graft loss in 2 patients.

*Conclusions: Treatment of BKV with IVIG 0.1 g/kg weekly for 10 weeks without additional alternative therapies provided a significant reduction in BK viral log10 at 3 and 6 months post IVIG in KTR with persistent BKV despite reduction in IS. Further comparative studies are needed however this review highlights the potential efficacy of weekly IVIG in KTR not on additional anti-virals.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Girone G, Asch W. Treatment of BK Virus with Weekly Intravenous Immunoglobulin in Adult Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/treatment-of-bk-virus-with-weekly-intravenous-immunoglobulin-in-adult-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences